



## Strict Adherence to Medication Safety and Pharmacist Responsibilities under PhilHealth GAMOT Benefit

This advisory is in accordance with the PhilHealth Circular (PC) No. 2025-0013 or the Nationwide Implementation of Guaranteed and Accessible Medications for Outpatient Treatment (PhilHealth GAMOT) along with the Professional Regulatory Board of Pharmacy Resolution No. 23, Series of 2021 (Resolution Promulgating and Prescribing the Code of Ethics of the Pharmacy Profession), emphasizing the critical role pharmacists play in patient safety, verification of prescriptions, and the prevention of medication errors.

Following the provisions of PC No. 2025-0013, all Pharmacist of GAMOT Facilities are explicitly empowered and obligated to act as the final safety checkpoint before dispensing medications, in consonance with their professional responsibility under the Code of Ethics. The PC No. 2025-0013 Section V.C.5.e states :

*"If any form of inconsistencies to the prescription is present, the pharmacist may seek confirmation with the authorized physician regarding the authenticity of the prescription. At the same time, the pharmacist reserves the right to withhold the dispensing of any inappropriate medications that have been prescribed (e.g., drug interactions, allergic reactions) and instruct the beneficiary to return to the authorized physician for appropriate action."*

Pursuant to the Performance Commitment signed by the GAMOT Facility upon accreditation, all facilities are reminded of their warranted representations and obligations to comply with all laws and administrative issuances. Violation of the Performance Commitment may result in the denial of claims, suspension, or revocation of PhilHealth accreditation.

Any observed non-compliance with the provisions of R.A. No. 10918 (Philippine Pharmacy Act) and R.A. No. 8981 (PRC Modernization Act of 2000), the Corporation may bring the matter to the attention of the Professional Regulation Commission (PRC) for appropriate administrative action.

For the information and guidance of all concerned.

**(Sgd.) EDWIN M. MERCADO, MD, MHA, MMSc**

President and Chief Executive Officer

Date signed: December 17, 2025